Skip to content
sellWeak10b5-1 plan

Randall Moreadith sold $16k of SER

Chief Scientific Officer at Serina Therapeutics, Inc.. 6,500 shares at an average of $2.50, traded Jan 13, 2026, filed Jan 14, 2026.

Warning score
0
Value
$16k
6,500 shares
Holdings after
0
-120% from before
From 52-week low
+29%
low $1.91, close $2.46
From 52-week high
-61%
high $6.31, as of Jan 13, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $16k at market
    0
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -31.5%, 3m -24.0%, 6m -27.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SEROct 9, 2026 · close 2.00
Since filing Jan 14, 2026: -25.1%SPY +13.6% · excess -38.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001301120-26-000004, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 13, 2026MOption exercise
Common Stock10b5-1
+5,416$0.06$3255,416Jan 14, 2026
Jan 13, 2026SOpen-market sale
Common Stock10b5-1
-5,416$2.50$14k0Jan 14, 2026
Jan 14, 2026MOption exercise
Common Stock10b5-1
+1,084$0.06$651,084Jan 14, 2026
Jan 14, 2026SOpen-market sale
Common Stock10b5-1
-1,084$2.50$2,7130Jan 14, 2026
Jan 13, 2026MOption exercise
Stock Option (right to buy)derivative10b5-1
-5,416$0.00$0333,770Jan 14, 2026
Jan 14, 2026MOption exercise
Stock Option (right to buy)derivative10b5-1
-1,084$0.00$0332,686Jan 14, 2026

Related signals

Other insiders at Serina Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
31Weak
SERbuy
Serina Therapeutics, Inc.
Stephen K. Brannan
director
$2,030
1,000 shares
-
46Moderate
SERbuy 3
Serina Therapeutics, Inc.
Jay Venkatesan
director
$1,048
589 shares
-
36Weak
SERbuy
Serina Therapeutics, Inc.
Karen J Wilson
director
$18k
10,100 shares
-
52Moderate
SERbuy 3
Serina Therapeutics, Inc.
Karen J Wilson
director
$37k
20,000 shares
-
46Moderate
SERbuy 3
Serina Therapeutics, Inc.
Richard Peter Marshall
director
$20k
12,183 shares
-
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$19k
6,500 shares
-100%
10Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$98k
39,000 shares
-100%
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$20k
6,500 shares
-100%
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$23k
6,500 shares
-100%
0Weak
SERsell10b5-1
Serina Therapeutics, Inc.
Randall Moreadith
Chief Scientific Officer
$7,375
2,500 shares
-100%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Randall Moreadith sold $16k of SER | InsiderTell